Arcutis Biotherapeutics(ARQT)

Focus: Arcutis is a public biotech company focused on reformulated topical dermatology products, currently generating revenue from ZORYVE (roflumilast) for dermatological indications. The company operates as a late-stage clinical-stage biotech with emerging commercial scale.

Dermatology

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

11+1 this month

Stable — net +1 jobs in 30d

8 added, 7 removed. Backfill posture.

Should You Work at Arcutis Biotherapeutics?

AI assessment

Best-fit for dermatology-focused scientists and commercial professionals willing to bet on pipeline execution; avoid if you prioritize financial stability or diversified revenue streams.

Why Work Here

Commercial inflection point: ZORYVE revenue grew from $4M (FY2024) to $60M (FY2025), demonstrating market traction and expansion opportunity

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$60M

Key Products

ZORYVE

Chronic Obstructive Pulmonary Disease / Dermatological indications

$7M Part D

Growth

Help build intelligence for Arcutis Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep dermatology pipeline: 4 roflumilast programs in Phase 1–3 across plaque psoriasis, seborrheic dermatitis, chronic hand eczema, and atopic dermatitis represent significant label-expansion upside

Public company stability with focused mission: established ticker (ARQT) and $71M cash runway enable execution without emergency fundraising

Watch Out For

Extreme revenue concentration risk: 100% dependency on ZORYVE creates existential vulnerability if market adoption plateaus or competitors emerge
Burning capital at 186% R&D intensity with negative net income (-$262M FY2025): company is spending $1.86 on R&D for every $1 in revenue, requiring near-term pipeline wins to justify burn rate

Generated by Claude from Arcutis Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Anchor product driving 100% of revenue with 15x year-over-year growth; patent protection extends to 2042, providing long runway for expansion.

Pipeline & Clinical Trials

roflumilast

Atopic Dermatitis

Phase 1

ARQ-154 Foam 0.3%

Psoriasis

Phase 1

Clinical Trials (1)

NCT07340216Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Phase 1

ARQ-234

Atopic Dermatitis (AD)

Phase 1

Clinical Trials (1)

NCT07453602Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Phase 1

ARQ-151- cream 0.3%

Plaque Psoriasis

Phase 1

Clinical Trials (1)

NCT04279119Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis

Phase 1

ARQ-151 cream 0.15%

Atopic Dermatitis (Eczema)

Phase 1

Clinical Trials (1)

NCT04156191Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Phase 1

ARQ-252 cream 0.3%

Chronic Hand Eczema

Phase 1/2

Clinical Trials (1)

NCT04378569Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Phase 1/2

ARQ-151 cream 0.5%

Psoriasis

Phase 1/2

Clinical Trials (1)

NCT03392168Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Phase 1/2

ARQ-151 cream 0.3%

Psoriasis

Phase 2

Clinical Trials (1)

NCT04655313Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Phase 2

ARQ-252 cream 0.3%

Vitiligo

Phase 2

Clinical Trials (1)

NCT04811131Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Phase 2

PDE4 inhibitor

Chronic Hand Eczema

Phase 2

ARQ-151 cream 0.3%

Psoriasis

Phase 2

Clinical Trials (1)

NCT04746911Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Phase 2

ARQ-154

Seborrheic Dermatitis

Phase 2

Clinical Trials (4)

NCT04973228Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Phase 3

NCT04091646Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

roflumilast

Plaque Psoriasis

Phase 3

Clinical Trials (5)

NCT07560618Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

Phase 4

NCT04845620Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

roflumilast

Seborrheic Dermatitis

Phase 3

Interview Prep Quick Facts

Founded: 2016

Portfolio: 2 approved products, 28 clinical trials

Top TAs: Immunology, Dermatology, Gastroenterology

Publications: 25 in PubMed

SEC Filings: 2 available

Open Roles: 11 active jobs

Portfolio Health

Growth1 (50%)

Peak1 (50%)

2 total products

Therapeutic Area Focus

Immunology

2 marketed21 pipeline

6 pipeline

2 marketed

2 marketed

2 marketed

Financials (FY2025)

Revenue

$60M1517%

R&D Spend

$111M(186%)39%

Net Income

-$262M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Pediatric dermatology

2026

PMID:41795905

Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 Years.

NCT04128007Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Phase 2

NCT04773587Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Phase 3

Respiratory

2 marketed

Psychiatry

1 marketed

Pediatric dermatology

2026

PMID:40862624

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Arcutis Biotherapeutics(ARQT)

Should You Work at Arcutis Biotherapeutics?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Recent News · Arcutis Biotherapeutics(3)

Open Jobs (11)

Associate Director Primary Care Sales Operations

Associate Director Regulatory Affairs

Overlay Therapeutic Sales Specialist - Detroit, MI

Therapeutic Sales Specialist - Princeton, NJ

Overlay Therapeutic Sales Specialist - Houston, TX

Senior Manager, Digital Marketing

Associate Director Post Marketing Quality

Exec Director Associate General Counsel, Strategic Transactions

Senior Manager Clinical Supply Chain

Senior Manager HCP Digital Marketing

Therapeutic Sales Specialist - San Francisco, CA

Financials (FY2025)

Hiring Trend

Research Publications(10)